A Phase 1 interventional study of Rabeprazole Sodium 10mg and Rabeprazole Sodium 20mg in Gastroesophageal Reflux Disease, sponsored by Yungjin Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-24.
Sponsored by Yungjin Pharm. Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 1, and was the 40th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
Yungjin Pharm. Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Yungjin Pharm. Co., Ltd. has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects
This study is to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: 1 tablet administered before the breakfast during 7 days
Drug: Rabeprazole Sodium 10mg
Part B: 1 tablet administered before the breakfast during 7 days
Drug: Rabeprazole Sodium 20mg
Part A: 1 tablet administered before the breakfast during 7 days
Also known as: Reference drug
Part B: 1 tablet administered before the breakfast during 7 days
Also known as: Reference drug
Integrated gastric acidity
Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 7th dose
Time frame: From Day 1 up to Day 28
AUCt,ss
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 1 st dose
Evaluateion PD Rabeprazole after multiple dose
Time frame: 24 hours
Percent of time with gastric pH>4 for 24 hour interval after 1st and 7th dose
Evaluateion PD Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 28
Mean and median gastric pH after 1st and 7th dose
Evaluateion PD Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 28
AUCτ
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Cmax
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Tmax
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
t1/2
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
CL/F
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Vz/F
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Cmin,ss,
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Cmax,ss
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Cav,ss,
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Tmax,ss
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
t1/2,ss
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
CLss/F
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Vss/F
Evaluateion PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Ran from Jan 2021 to primary completion in Jun 2021, 4 months.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 4 months is close to that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole
Yungjin Pharm. Co., Ltd.